![]() Tegoprubart (formerly known as AT-1501) is an investigational, humanized IgG1 anti-CD40L antibody with high affinity for the CD40 ligand (CD40L, also called CD154). “We believe this strategic agreement offers a promising step towards helping xenotransplantation become a clinical reality.” Gros, M.D., Chief Executive Officer of Eledon. “We are excited to partner with eGenesis in support of our combined commitment to offer effective solutions for patients requiring organ or cellular transplantation,” said David-Alexandre C. “This collaboration agreement provides eGenesis with access to tegoprubart, an anti-CD40L immune modulating therapy that we believe may be a critical part of an effective immunosuppression regimen for our ongoing and future preclinical studies and could help position us to achieve successful clinical translation into humans.” “Despite significant recent progress and momentum in the field of xenotransplantation, improving organ compatibility to prevent rejection remains an ongoing challenge,” said Michael Curtis, Ph.D., Chief Executive Officer of eGenesis. ![]() The collaboration has the potential to span multiple eGenesis programs including kidney, heart and islet cell transplant. (“eGenesis”) and Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that they have entered into a collaborative research agreement under which eGenesis will gain access to Eledon’s anti-CD40L antibody candidate, tegoprubart, for eGenesis’ ongoing preclinical research and development studies of human-compatible organs and cells for the treatment of organ failure. 09, 2023 (GLOBE NEWSWIRE) - eGenesis, Inc. Establishes framework for use of tegoprubart for preclinical xenotransplantation studies in support of eGenesis’ kidney, heart and islet cell programs-ĬAMBRIDGE, Mass. The final therapeutic regimen that allows survival of a discordant xenograft is likely to involve a combination of ‘modified’ functional genes in the donor organ, the development of immunological tolerance to pig antigens and administration of novel therapeutic agents, including immunosuppressants, that can control natural killer (NK) cell and monocyte mediated responses.-Agreement leverages Eledon’s investigational anti-CD40L antibody, tegoprubart, as part of eGenesis’ immunosuppression regimen that prevents xenotransplant rejection in nonhuman primate recipients. Experimental pig-to-primate organ xenotransplantation is currently under way, and results show increased transplant function from minutes to days and weeks. Of greater significance is that nuclear transfer offers the ability to target gene insertion selectively to specific gene loci and to delete specific genes in the pig. Transgenic pigs required for xenotransplantation will soon be generated at a greater efficiency and precision using nuclear transfer and cloning when compared to pronuclear injection. DXR is likely to be controlled by transgenic inhibition of endothelial cell activation (e.g. transgenic modifications to express human complement-regulatory proteins or removal or displacement of alphaGal epitopes). antibodies or complement depletion or inhibition and tolerance induction) and those directed at the donor (e.g. Strategies to diminish immunogenicity following xenotransplantation can be divided into two approaches: those directed at the recipient (e.g. An improved understanding of the immune recognition and rejection of xenografts has resulted in new therapies that can partially overcome hyperacute rejection (HAR), delayed xenograft rejection (DXR) or acute vascular xenograft rejection. pig organs) used for human transplantation are normally destroyed by the host within minutes by hyperacute xenograft rejection. The pig stands out as the most suitable donor animal for humans however, xenografts (e.g. ![]() The transplantation of organs and tissues between animal species, or xenotransplantation, is the focus of a growing field of research, owing primarily to the increasing shortage of allogeneic donor organs.
0 Comments
Leave a Reply. |